Included in the formulation
Pharmacodynamics:In natural conditions, the component of the blood coagulation system is formed by the interaction of thromboplastin with prothrombin, resulting in the formation of a blood clot. The activity of the drug is determined in units (EA). For 1 unit of activity take the amount of thrombin, the use of which leads to clotting of blood plasma for 30 s at a temperature of +37 °C or purified fibrinogen for 15 seconds.
Pharmacokinetics:Means for topical application, systemic action on the body does not have.
Indications:It is used topically to stop bleeding from small vessels of the parenchymal organs during abdominal operations, as well as surgical interventions on the brain, liver and kidneys. Used as a local haemostatic agent for bleeding from the nose and gums in Verlhof disease, hypoplastic and aplastic anemia.
XVIII.R50-R69.R58 Bleeding, not elsewhere classified
Contraindications:Individual intolerance.
Carefully:
Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category B.It is applied topically in emergency cases, does not have a systemic effect on the body.
Dosing and Administration:It is used as a local hemostatic agent. The drug solution is applied to a sterile gauze swab or injected into the haemostatic sponge with a syringe. The tampon is applied to the wound and removed after a bleeding stop, the hemostatic sponge is left - subsequently it resolves.
Side effects:Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:Intravascular and intramuscular injection of thrombin is not allowed - thrombosis and thromboembolism are possible.